AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Sphingosine-1-phosphate phosphatase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BX95

UPID:

SGPP1_HUMAN

Alternative names:

Sphingosine-1-phosphatase 1; Sphingosine-1-phosphate phosphohydrolase 1

Alternative UPACC:

Q9BX95; B2RAH0; Q9H189

Background:

Sphingosine-1-phosphate phosphatase 1, known for its critical role in dephosphorylating sphingosine 1-phosphate (S1P) and related compounds, does not act on other phospholipids. This enzyme is pivotal in recycling sphingosine into the sphingolipid synthesis pathway, regulating the bioactive sphingolipid metabolite S1P levels, which in turn influences diverse biological processes. It also plays a role in ceramide synthesis, sphingosine recycling, and the regulation of apoptosis and autophagy through modulation of ceramide and S1P levels.

Therapeutic significance:

Understanding the role of Sphingosine-1-phosphate phosphatase 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.